2026年11月5日星期四
M
Atlante Universale
Notizie flash globali
Japan's Yamato targets 'leaner' delivery service in push for profit: president— 日经 Nikkei AsiaToyota to bring Celica back to premier rally racing after 32-year break— 日经 Nikkei AsiaU.S. Steel grows to 40% of Nippon Steel profit as prices surge— 日经 Nikkei AsiaThe price of building Japanese stealth frigates in Australia— 日经 Nikkei AsiaMcDonald's wages war on KFC in Japan as consumers crave chicken— 日经 Nikkei AsiaJapan's Koito looks to keep lighting way with smart automotive lamps— 日经 Nikkei AsiaAnalysis: How a secret feud ignited Xi Jinping's governance drive— 日经 Nikkei AsiaJapan lender leads $600m credit line to help Malaysia's Petronas cut CO2— 日经 Nikkei AsiaJapan's Yamato targets 'leaner' delivery service in push for profit: president— 日经 Nikkei AsiaToyota to bring Celica back to premier rally racing after 32-year break— 日经 Nikkei AsiaU.S. Steel grows to 40% of Nippon Steel profit as prices surge— 日经 Nikkei AsiaThe price of building Japanese stealth frigates in Australia— 日经 Nikkei AsiaMcDonald's wages war on KFC in Japan as consumers crave chicken— 日经 Nikkei AsiaJapan's Koito looks to keep lighting way with smart automotive lamps— 日经 Nikkei AsiaAnalysis: How a secret feud ignited Xi Jinping's governance drive— 日经 Nikkei AsiaJapan lender leads $600m credit line to help Malaysia's Petronas cut CO2— 日经 Nikkei Asia

Sitagliptin, a repurposed diabetes drug, overcomes gemcitabine resistance in pancreatic cancer via ribonucleotide reductase inhibition: SITGEM-CARE phase 2 trial

Fonte Nature 生命科学1 giorni fa
Sintesi del contenuto

Questo sito fornisce solo titoli e indici di riepilogo; il contenuto completo e i diritti d'autore appartengono all'editore originale. Clicca sul link all'articolo originale per leggerlo.

Vai all'articolo originale
Canale di appartenenza
Scienza
Regione di appartenenza
Prospettiva globale
Lingua originale
English
Numero di voce
science-f81c0280

Comments 0 comments

No comments yet. Be the first.

Sitagliptin, a repurposed diabetes drug, overcomes gemcitabine resistance in pancreatic cancer via ribonucleotide reductase inhibition: SITGEM-CARE phase 2 trial · Atlante Universale